Published by Josh White on 8th August 2022
(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).
URL: http://www.digitallook.com/dl/news/story/32876385/...